Trial Profile

A Phase 2b clinical study evaluating oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Aug 2026 According to a Vaxart media release, The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, in the first half of 2027.
07 Jul 2026 Results published in the Media Release
25 Jun 2026 According to a Vaxart media release, overall funding available for the trial is now approximately $345 million. The latest modification allows for the release of approximately $29 million for completion of the trial and exploratory analyses

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com